Φορτώνει......
Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia
Acute myeloid leukemia (AML) is a heterogeneous myeloid neoplasm with poor clinical outcome, despite the great progress in treatment in recent years. The selective Bcl-2 inhibitor venetoclax (ABT-199) in combination therapy has been approved for the treatment of newly diagnosed AML patients who are...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Cell Death Dis |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Nature Publishing Group UK
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7501858/ https://ncbi.nlm.nih.gov/pubmed/32948748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-02972-2 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|